Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Assets (2016 - 2025)

Anaptysbio's Assets history spans 10 years, with the latest figure at $364.4 million for Q4 2025.

  • For Q4 2025, Assets fell 24.69% year-over-year to $364.4 million; the TTM value through Dec 2025 reached $364.4 million, down 24.69%, while the annual FY2025 figure was $364.4 million, 24.69% down from the prior year.
  • Assets reached $364.4 million in Q4 2025 per ANAB's latest filing, up from $353.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $643.1 million in Q4 2021 to a low of $335.2 million in Q2 2025.
  • Average Assets over 5 years is $482.1 million, with a median of $468.1 million recorded in 2023.
  • Peak YoY movement for Assets: skyrocketed 57.7% in 2022, then decreased 28.44% in 2025.
  • A 5-year view of Assets shows it stood at $643.1 million in 2021, then dropped by 5.08% to $610.4 million in 2022, then decreased by 25.88% to $452.4 million in 2023, then rose by 6.95% to $483.8 million in 2024, then fell by 24.69% to $364.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Assets are $364.4 million (Q4 2025), $353.1 million (Q3 2025), and $335.2 million (Q2 2025).